Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Bought by Zions Bancorporation N.A.

Zions Bancorporation N.A. lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 201,882 shares of the medical technology company’s stock after buying an additional 28,702 shares during the period. Zions Bancorporation N.A.’s holdings in Alphatec were worth $1,853,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ATEC. R Squared Ltd bought a new stake in Alphatec during the 4th quarter valued at $29,000. Nisa Investment Advisors LLC raised its stake in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 4,234 shares in the last quarter. Newton One Investments LLC acquired a new stake in Alphatec in the fourth quarter worth about $50,000. XTX Topco Ltd bought a new position in Alphatec in the 3rd quarter valued at about $69,000. Finally, AlphaQuest LLC acquired a new position in Alphatec during the 4th quarter valued at about $80,000. 66.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Trading Down 1.6 %

Shares of NASDAQ ATEC opened at $10.32 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.54. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -8.06 and a beta of 1.39. The business has a fifty day simple moving average of $10.94 and a 200-day simple moving average of $8.92.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the completion of the sale, the chief executive officer now directly owns 6,152,544 shares in the company, valued at approximately $74,015,104.32. This trade represents a 0.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now owns 502,311 shares in the company, valued at $5,379,750.81. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 337,321 shares of company stock worth $3,828,060. Corporate insiders own 22.80% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.